As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Chimeric antigen receptor (CAR) T cells therapies, as a novel modality in cancer immunotherapy, provide a quantum leap in the treatment of cancer. BMC Cancer and BMC Biotechnology together present the latest collection of articles on the advances in CAR-T immunotherapy covering the entire range of advances from lab to clinic. Click on highlight to read the the full collection of articles.
Click here to view which Articles have been shared most in the last 6 months!
Featured review: Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico
Gallbladder cancer is a rare malignancy of the biliary tract with a poor prognosis, frequently presenting at an advanced stage. While rare in the United States overall, gallbladder cancer has an elevated incidence in geographically distinct locations of the globe including Chile, North India, Korea, Japan and the state of New Mexico in the United States. Rama R. Gullapalli, Associate Editor for BMC Cancer provides this review.
Featured video: Microparticles, breast cancer's secret weapon?
Featured review: A stepwise approach to constructing systematic reviews
Systematic reviews, with or without meta-analysis, play an important role today in synthesizing cancer research and are frequently used to guide decision-making. With a focus on cancer, first author, Prof Kelley, provides a practical, stepwise approach for systematically reviewing the literature and publishing the results.Read More
How do physicians and nurses perceive the benefits of clinical trial participation compared with standard care? Is it justified to claim that clinical trial participation improves outcomes for cancer patients? Zandra Nielsen et al. present their latest findings of a mixed-methods study in Scandinavia.
Aims and scope
- Cell and molecular biology
- Epidemiology, prevention and public health
- Experimental therapeutics and drug development
- Genetics, genomics and epigenetics
- Infection, immunity and cancer vaccines
- Medical and radiation oncology
- Surgical oncology, cancer imaging and interventional therapeutics
- Systems biology, post-genomic analysis and emerging technologies
- Supportive therapy, cancer burden and survivorship
Linda Gummlich, BMC Series, London, UK
Yanis Boumber, Fox Chase Cancer Center, USA
Ken Herrmann, Universitätsklinikum Essen, Germany
Alan Lefor, Jichi Medical University, Japan
Christophe Nicot, Kansas University Medical Center, USA
Stephen Povoski, The Ohio State University, USA
Dirk Vordermark, Martin Luther University Halle-Wittenberg, Germany
We are proud to finally present the publications from our cross-journal thematic series, Precision Oncology. This collection focuses on how precision oncology has shaped advances in the impact of non-coding RNAs in epigenetics and cancer, immunotherapy and tumor biology. Also of note are the technological developments for preclinical routines and the clinical significance of various therapies in breast, esophageal, liver, lung, ovarian cancers, among other types.
Read our highly accessed articles
Follow Nobel Prize laureates James P. Allison's and Tasuku Honjo's footsteps and experience the genesis of a new field of cancer therapy. BMC Cancer Editorial Board Member Dr. Sheng Guo from Pittsburgh University takes us on an exciting journey of discovery...
BMC Series Blog
2019 Journal Metrics
3.15 - 2-year Impact Factor
3.432 - 5-year Impact Factor
1.021 - Source Normalized Impact per Paper (SNIP)
1.186 - SCImago Journal Rank (SJR)
Social Media Impact